To include your compound in the COVID-19 Resource Center, submit it here.

Juno gets ADORA2A inhibitor in RedoxTherapies takeout

Juno Therapeutics Inc. (NASDAQ:JUNO) acquired RedoxTherapies Inc. (Boston, Mass.) for $10 million in

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE